12:00 AM
 | 
Dec 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pomalidomide: Phase II data

A Phase II trial in 70 patients with MM refractory to both Revlimid lenalidomide and Velcade bortezomib showed that 2 and 4 mg dose regimens of daily pomalidomide plus dexamethasone produced >=minor responses in 49% and 40% of patients, respectively....

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >